Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ..
Go back to Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ..| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 60.81 -0.87 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.68 | 52 Week High | $77.12 | |||
| Open | $61.50 | 52 Week Low | $49.03 | |||
| Day High | $61.81 | P/E | 39.49 | |||
| Day Low | $60.72 | EPS | $1.54 | |||
| Volume | 2,404,763 | |||||



